SCOPUS 정보 검색 플랫폼

Volumn 94, Issue 11, 2006, Pages 1759-1760

Pulmonary toxicity in patients treated with gemcitabine and a combination of gemcitabine and a taxane: Investigation of a signal using postmarketing data [1]

(2) Czarnecki, A a Voss, S a

a ELI LILLY AND COMPANY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; TAXANE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; HUMAN; LETTER; LUNG EDEMA; LUNG TOXICITY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESPIRATORY DISTRESS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745255070 PISSN: 00070920 EISSN: 15321827 Source Type: Journal
DOI: 10.1038/sj.bjc.6603161 Document Type: Letter

Times cited : (4)

References (5)

1
- 0036806170
- A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated phase IIIb and IV non-small cell lung cancer
- Bhatia S, Hanna N, Ansari R, Pletcher W, Einhorn L, Ng E, Sandler A (2002) A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated phase IIIb and IV non-small cell lung cancer. Lung Cancer 38: 73-77
- (2002) Lung Cancer , vol.38 , pp. 73-77
- Bhatia, S.¹ Hanna, N.² Ansari, R.³ Pletcher, W.⁴ Einhorn, L.⁵ Ng, E.⁶ Sandler, A.⁷

2
- 0035700740
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
- Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Safe 10: 483-486
- (2001) Pharmacoepidemiol Drug Safe , vol.10 , pp. 483-486
- Evans, S.J.W.¹ Waller, P.C.² Davis, S.³

3
- 4344564261
- A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
- Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, A'Hern R, Gibbens I, Jenkins A, Shah R, Cole C, Pizzada O, Kaye S (2004) A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 91: 627-632
- (2004) Br J Cancer , vol.91 , pp. 627-632
- Harries, M.¹ Moss, C.² Perren, T.³ Gore, M.⁴ Hall, G.⁵ Everard, M.⁶ A'Hern, R.⁷ Gibbens, I.⁸ Jenkins, A.⁹ Shah, R.¹⁰ Cole, C.¹¹ Pizzada, O.¹² Kaye, S.¹³

4
- 0033712619
- Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: Report of a phase I/II dose escalating study
- Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose escalating study. Eur J Cancer 36: 2329-2334
- (2000) Eur J Cancer , vol.36 , pp. 2329-2334
- Thomas, A.L.¹ Cox, G.² Sharma, R.A.³ Steward, W.P.⁴ Shields, F.⁵ Jeyapalan, K.⁶ Muller, S.⁷ O'Byrne, K.J.⁸

5
- 30644459425
- SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer
- Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S, Rustin GJS (2006) SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 94: 62-68
- (2006) Br J Cancer , vol.94 , pp. 62-68
- Vasey, P.A.¹ Atkinson, R.² Osborne, R.³ Parkin, D.⁴ Symonds, R.⁵ Paul, J.⁶ Lewsley, L.⁷ Coleman, R.⁸ Reed, N.S.⁹ Kaye, S.¹⁰ Rustin, G.J.S.¹¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.